Pfizer Unveils $214 Million Biotech Facility in Sweden
Pharmaceutical giant Pfizer, Inc., (New York, NY) has opened a new 64,600-square-foot biotech plant in Strangnas, Sweden.
Pharmaceutical giant Pfizer, Inc., (New York, NY) has opened a new 64,600-square-foot biotech plant in Strängnäs, Sweden. The new facility is expected to be commercially operational in 2011.
Products made at the $214-million plant will include Pfizer's human growth hormone, or Genotropin, along with the drug Somavert for acromegaly, and drugs based on E. coli and yeast.
The new plant will be connected to the existing facility in Strängnäs, which will facilitate the flow of material as well as personnel. An older part of the Strängnäs facility will close when the new facility is fully approved, said a Pfizer representative.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
